You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨香雪製藥三連板 引進抗腫瘤新藥產品
格隆匯 12-19 11:07
格隆匯12月19日丨香雪製藥(300147.SZ)三連板,報8.99元,總市值59.5億元。

香雪製藥12月16日晚間公告,公司近日與Athenex簽署授權協議,就其在研產品口服紫杉醇、口服伊立替康和KX2-391軟膏的研發、商業化進行合作。公司將向Athenex支付不超1.8億美元的授權許可費用和研發、銷售里程碑費用;以及相應授權使用費用及控制權變更費用。此次通過授權方式與Athenex合作引進抗腫瘤新藥產品,將豐富公司的癌症產品組合,使公司成為抗腫瘤藥物研發的專業公司。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account